Announcement PDF MRI LIVER FIBROSIS DEVICE EPoC CLINICAL TRIAL PRELIMINARY RESULTS WEBINAR Resonance Health Ltd (Resonance or Company) (ASX: RHT) expects to release the preliminary results of its Non-invasive MRI Liver Fibrosis Medical Device extended-proof-of concept (EPoC) clinical trial on Wednesday 28 October 2026. Investors are invited to join a webinar hosted by Andrew Harrison, MD & CEO, and Dr Wenjie Pang, Chief Scientific OVicer, on Wednesday 28 October 2026 at 10:00 a.m. Australian Western (Perth) Time (AWST). As reported previously, the initial proof-of-concept for this highly prospective new technology showed strong predictive capability to identify liver fibrosis (see ASX release, 21 Dec 2022). The EPoC clinical trial is more extensive than the initial trial and is a critical inflection point in the roadmap towards certifying a new non-invasive MRI-based liver fibrosis medical device. Liver disease is a leading cause of mortality worldwide. Most notably, these diseases include metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction- associated steatohepatitis (MASH); the most common liver diseases worldwide aVecting an estimated one-quarter of the world’s population1 . Early identification of liver fibrosis is essential to managing liver disease. The current gold standard for identifying and assessing liver fibrosis – liver biopsy – is invasive and comes with various risk and cost factors which are largely mitigated by using non-invasive methods. Andrew Harrison, MD & CEO said: “I invite you to join us for the release of our preliminary results from our MRI liver fibrosis device EPoC clinical trial as we talk though the trial, methods and key outcomes”. You can attend via the link: https://investors.resonancehealth.com/webinars/yEMgGy-mri- liverfibrosis-device-clinical-trial-preliminary-results-webinar Additionally, a video recording of the presentation will be available within 24 hours following the presentation at the Resonance Health Investor Centre homepage: https://investors.resonancehealth.com/ This announcement has been authorised for release in accordance with the delegated authority of the Board of Directors of Resonance Health Ltd. For further information: Andrew Harrison – Managing Director E: andrewh@resonancehealth.com P: +61 8 9286 5300 Resonance Health Ltd ABN: 96 006 762 492 141 Burswood Road, Burswood, WA 6100, AUSTRALIA Postal: PO Box 108, Victoria Park, WA 6979, AUSTRALIA www.resonancehealth.com T + 61 8 9286 5300 info@resonancehealth.com ASX Announcement – 20 October 2026 About Resonance Health Resonance Health is an Australian healthcare technology and services company. The Company’s services are used globally by clinicians in the management of human diseases and by pharmaceutical and therapeutic companies in their clinical trials. Resonance Health has gained endorsement by leading physicians worldwide for providing high-quality quantitative assessments essential in managing diseases and drug development. Resonance Health’s dedication to scientific rigour and quality has enabled it to achieve regulatory clearances for a range of Software-as-Medical Devices (SaMDs) in the USA, Europe, UK, and Australia, and to proudly carry ISO 13485 certification for the design and manufacture of medical devices. Regulatory cleared SaMD products, some of which incorporate Artificial Intelligence (AI), include: § FerriScan®, a core-lab product that provides an accurate assessment of liver iron concentration (LIC) through non-invasive MRI-based technology, for use in the assessment of individuals with iron overload conditions. Internationally recognised as the gold standard in LIC assessment. § FerriSmart®, an AI-trained, non-invasive MRI-based device for the automated real-time assessment of LIC in participants, calibrated against the global gold standard, FerriScan®. § HepaFatScan®, an MRI-based solution which provides a reliable non-invasive assessment of liver- fat in liver tissue for use in the assessment of individuals with confirmed or suspected fatty-liver- disease. § HepaFatSmart ®, an AI-trained, non-invasive device for the automated real-time multimetric assessment of liver-fat in participants, for the assessment of individuals with confirmed or suspected fatty liver disease. § LiverSmart®, an AI-trained, non-invasive MRI-based multi-parametric device combining FerriSmart® and HepaFat-AI® into a consolidated report providing accurate assessment of LIC and liver fat. § CardiacT2*, the most widely accepted MRI method for assessing heart iron loading. Resonance Health oUers a dual analysis of FerriScan® and CardiacT2*. The Company has a development pipeline of additional medical imaging analysis products and services, including the MRI Liver Fibrosis Project, aimed at accurately assessing the presence and progression of liver fibrosis utilising non-invasive MRI analysis The Company also has a clinical trials business which both manages clinical trials in Australia and includes the site management operations of TrialsWest. Stakeholders, including clinicians, participants, and shareholders, are encouraged to register their interest at www.resonancehealth.com and to follow Resonance Health on LinkedIn. 1 CoQer TG, Rinella M (2020) Nonalcoholic FaQy Liver Disease 2020: The State of the Disease. Gastroenterology 158(7):1851–1864. hQps://doi.org/10.1053/j.gastro.2020.01.052 PMID: 32061595 Page 2